@article{3077991,
    title = "(E)-(1-(4-ethoxycarbonylphenyl)-5-(3,4-dimethoxyphe nyl)-3-(3,4-dimethoxystyryl)-2-pyrazoline: Synthesis, characterization, dna-interaction, and evaluation of activity against drug-resistant cell lines",
    author = "Matiadis, D. and Mavroidi, B. and Panagiotopoulou, A. and Methenitis, C. and Pelecanou, M. and Sagnou, M.",
    journal = "MolBank",
    year = "2020",
    volume = "2020",
    number = "1",
    publisher = "MDPI AG",
    doi = "10.3390/M1114",
    abstract = "(E)-1-(4-Ethoxycarbonylphenyl)-5-(3,4-dimethoxyphenyl)-3-(3,4-dimethoxystyryl)-2-pyrazoline was synthesized via the cyclization reaction between the monocarbonyl curcuminoid (2E,6E)-2,6-bis(3,4-dimethoxybenzylidene)acetone and ethyl hydrazinobenzoate in high yield and purity (>95% by High-performance liquid chromatography (HPLC)). The compound has been fully characterized by1H,13C NMR, FTIR, UV-Vis and HRMS and its activity was evaluated in terms of its potential interaction with DNA as well as its cytotoxicity against resistant and non-resistant tumor cells. Both DNA thermal denaturation and DNA viscosity measurements revealed that a significant intercalation binding takes place upon treatment of the DNA with the synthesized pyrazoline, causing an increase in melting temperature by 3.53 ± 0.11 °C and considerable DNA lengthening and viscosity increase. However, neither re-sensitisation of Doxorubicin (DO X)-resistant breast cancer and multidrug resistance (MDR) reversal nor synergistic activity with DOX by potentially increasing the DOX cell killing ability was observed. © 2020 by the authors. Licensee MDPI, Basel, Switzerland."
}